EU approval HeartMate 11

Next-Generation Cardiac Assist Device (HeartMate II) for Long-term Cardiac Support in EU
On Nov. 7, the European Commission approved a next-generation left ventricular assist system (LVAS; HeartMate II, made by Thoratec Corporation) to provide long-term support for patients in advanced-stage heart failure.
The continuous-flow implantable device is approximately one fifth the size of the company's HeartMate XVE product (which is approved for use in the United States) and may be used in a broader range of body sizes.
It is designed to have a much longer functional life and operate more quietly compared with currently approved pulsatile devices.
The approval was based on data from the first 20 patients implanted with the device in a European study and a US phase 1 clinical trial (HeartMate II Axial Flow LVAS: Suitability for Advanced Congestive Heart Failure). The data reflected more than 7,900 days of cumulative support with individual use ranging from 1 to 717 days.
Results from the phase 1 trial in 34 patients (median support, 160 days; range, 6 - 562 days) showed that 43% of 14 patients supported by the device for 3 months or longer improved by 3 New York Heart Association functional classes. In addition, 75% of patients demonstrated improved exercise capacity compared with baseline, as evaluated by increases in walking distance.
No device-related deaths or pump failures were reported, and 2 pump-related infections occurred.
According to a company news release, the device's potential for restoring hemodynamic function may render it suitable for use in a wider range of advanced-stage heart failure patients to significantly improve their survival and quality of life.
The device is currently undergoing a pivotal clinical trial in the United States for both destination therapy (DT) and bridge-to-transplantation (BTT) indications. Thus far, 102 patients have been enrolled in the study. The DT group (n = 50) will be evaluated on survival, rate of neurologic events, and device reliability in a 2-year composite end point; the primary end point of the BTT group (n = 52) will be rate of survival to transplantation.
source: medscape

Comments

Popular posts from this blog

Inflammatory Bowel Disease an Independent Risk Factor for MI

The Council of the European Union has decided that the European Medicines Agency (EMA) will be relocated to the City of Amsterdam.

Inflamation and Alzheimer disease